• Moderna in continuation pattern.
  • Moderna stock has been hammered in November.
  • MRNA shares are down nearly 30% this month.

Moderna (MRNA) stock rallied just over 3% on Wednesday in a continuation of recent small gains seen after the tumultuous hammering the stock has suffered this month. Moderna shares are down 27% over the last month despite recovering somewhat this week, up 6% now. Moderna is still snapping back after stretching too far during the pandemic. The pace of earnings growth has slowed despite the company exploding due to the coronavirus pandemic. Vaccine uptake has likely peaked, and revenue growth slowing will see a reevaluation of the underlying share price. This is what is currently happening. 

Moderna (MRNA) stock news

While many are arguing the development of antiviral pills is what is hurting Moderna's share price the most, we actually feel it was the weak earnings report. This highlighted a few things. Number one: Moderna is way too reliant on one stream of revenue, that of a covid vaccine. It does have numerous other candidates in trial stages, but only a few have reached phase-3 trials. It takes years for treatments to go through stage trials. Covid did see this process speed up, but it will be back to multiple-year development timelines from now on. What the earnings highlighted the most was a revenue growth slowdown. Once that showed up, it was inevitable that investors would reassess and rebalance their Moderna holdings. 

Just in case you are not aware, other headwinds exist. These include the development of antiviral treatments for covid by both Pfizer (PFE) and Merck (MRK) to continuing haggles, which may turn legal, between Moderna and the US government over intellectual property rights for the development of Moderna's covid vaccine. 

Moderna (MRNA) stock forecast

The move remains in our view a consolidation of recent losses. A consolidation means a continuation phase is likely, and so a break lower is the most probable outcome. Only breaking the strong resistance from $255 to $265 will change our view. This is the 200-day moving average and the yearly volume-weighted average price (VWAP), so it is a strong resistance to break above. Instead, we are looking for a break lower to $188.41 and then $157, where it will be time to reevalaute the argument.

MRNA 1-day chart

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news Join Telegram

Recommended content

Recommended content

Editors’ Picks

EUR/USD remains pressured near 1.0250 amid renewed USD strength

EUR/USD remains pressured near 1.0250 amid renewed USD strength

EUR/USD remains pressured near 1.0250, undermined by a broad rebound in the US dollar after dismal Chinese data soured sentiment. Growing recession fears in the Eurozone amid the deepening energy crisis weigh down on the euro. 


GBP/USD drops towards 1.2100 as US dollar firms up

GBP/USD drops towards 1.2100 as US dollar firms up

GBP/USD is dropping towards 1.2100, as the US dollar rebounds amid a negative shift in risk sentiment amid weak China data. BOE’s Bailey shows readiness for a ‘review’ on UK PM Candidate Truss’ criticism. Critical UK data and Fed minutes are in focus this week. 


Gold closes the week above 50 DMA, what’s next? Premium

Gold closes the week above 50 DMA, what’s next?

Gold price is reversing Friday’s rebound above $1,800, as bears return at the start of the week. Buyers appear to lack follow-through upside momentum, as souring risk sentiment revives the US dollar’s safe-haven appeal.

Gold News

Tezos to provide bulls a generous exit before a 15% nosedive

Tezos to provide bulls a generous exit before a 15% nosedive

Tezos Price is hovering above a stable support level after facing an intense rejection. While this foothold is likely to provide harbor, it will not be for long. Investors must prepare for a long squeeze as bears make an elaborate move.

Read more

FXStreet Premium users exceed expectations

FXStreet Premium users exceed expectations

Tap into our 20 years Forex trading experience and get ahead of the markets. Maximize our actionable content, be part of our community, and chat with our experts. Join FXStreet Premium today!